|

Enasidenib Mesylate Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: 2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate, 2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1), AG-221 Mesylate, CC-90007, Enasidenib Methanesulfonate +1 more

Pipeline

Phase 2: 2

Top Sponsors

  • M.D. Anderson Cancer Center1
  • City of Hope Medical Center1

Indications

  • Cancer2
  • Acute Bilineal Leukemia1
  • IDH2 Gene Mutation1
  • Chronic Myelomonocytic Leukemia1
  • Refractory Acute Myeloid Leukemia1

Duarte, California1 trial

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

City of Hope Medical Center

Phase 2

Houston, Texas1 trial

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.